All updated as on -
There will be significant expansion in the oncolytic viral therapy industry, which is expected to reach US$ 45.08 million by the year 2030. As compared to US$ 9.40 million in 2023, this is a huge rise, indicating a tremendous CAGR of 26.1% from 2023 to 2030. Oncolytic viral therapy is becoming more widely used, and its revolutionary potential is a major factor in the industry's projected expansion.
The use of oncolytic viruses, which have been designed to specifically target and kill cancer cells while causing minimal damage to healthy cells, is a potential new direction in cancer treatment. Melanoma, lung, breast, and pancreatic cancers could all benefit greatly from this novel treatment approach. Growth in the market is being fueled by developments in viral engineering, increased knowledge of cancer biology, and promising results from clinical trials. New oncolytic virus medicines could significantly improve cancer therapy and the lives of patients as a result of ongoing research and collaboration between pharmaceutical corporations and academic institutions.
The design and specificity of oncolytic viruses have been improved thanks to ongoing developments in viral engineering techniques. To better target tumours and replicate inside cancer cells, researchers are creating modified viruses. These developments have helped oncolytic viral therapy become more successful and therapeutic. Our capacity to create targeted medicines rises in tandem with our knowledge of cancer biology. To combat cancer, oncolytic virus therapy exploits cancer cells' sensitivity to viral infection and their compromised antiviral defences. Oncolytic virus therapies have been developed to specifically target and destroy cancer cells while sparing normal healthy cells, thanks to our expanding understanding of cancer biology.
Oncolytic viral therapy has a great deal of untapped promise across a wide range of cancer subtypes and applications. There is potential to further investigate the efficacy of oncolytic viruses in treating various cancer subtypes and stages, as well as to broaden the indications for their usage. Treatment outcomes can be improved by combining oncolytic viral therapy with chemotherapy, immunotherapy, or targeted treatments. Preclinical and clinical research has demonstrated the potential of combining oncolytic viruses with other therapy. Better patient responses and therapeutic outcomes may be achieved through the investigation and optimisation of combination treatments.
Worldwide, the health care system was tested to its limits by the covid-19 epidemic. The significant global increase in covid-19 cases had a chilling effect on the development of the oncolytic viral therapy business as patients delayed treatment. It was also possible for patients with cancer to deteriorate rapidly. Furthermore, the lockdown impacted market expansion because it disrupted supply chains and prevented hospitals from installing new medical equipment.
Research and development of oncolytic virus therapies has seen a significant uptick in North America, particularly the United States. The region's established infrastructure for clinical trials, robust partnerships between academics and business, and innovation-friendly regulatory frameworks are all assets. Several oncolytic virus medicines have been approved in North America, and more clinical trials are underway. Market share estimates place this area's share at 45.2% or higher. There is significant interest in Europe in oncolytic virus therapy as well. There are now several clinical trials and research programmes in Europe that are evaluating oncolytic viruses as potential therapies for cancer. The availability of oncolytic virus medicines is made possible by the frameworks set up by European regulatory agencies for their approval and commercialization. About 30.7% of the global market is located in Europe.
Report Coverage
Global Oncolytic Virus Therapy research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Oncolytic Virus Therapy report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Oncolytic Virus Therapy competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Oncolytic Virus Therapy market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Oncolytic Virus Therapy market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Oncolytic Virus Therapy market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Targovax, PsiOxus Therapeutics Ltd., Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Transgene SA, VCN Biosciences, Lokon Pharma AB
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Oncolytic Virus Therapy market based on the below-mentioned segments:
Global Oncolytic Virus Therapy Market, By Type
Adenovirus
Herpes Simplex Virus (HSV)
Measles Virus
Reovirus
Vaccinia Virus
Vesicular Stomatitis Virus (VSV)
Others
Global Oncolytic Virus Therapy market, By Application
Solid Tumors
Hematological Malignancies
Global Oncolytic Virus Therapy Market, By End User
Hospitals
Cancer Research Institutes
Biopharmaceutical Companies
Global Oncolytic Virus Therapy market, Regional Analysis
The use of oncolytic viruses, which have been designed to specifically target and kill cancer cells while causing minimal damage to healthy cells, is a potential new direction in cancer treatment. Melanoma, lung, breast, and pancreatic cancers could all benefit greatly from this novel treatment approach. Growth in the market is being fueled by developments in viral engineering, increased knowledge of cancer biology, and promising results from clinical trials. New oncolytic virus medicines could significantly improve cancer therapy and the lives of patients as a result of ongoing research and collaboration between pharmaceutical corporations and academic institutions.
The design and specificity of oncolytic viruses have been improved thanks to ongoing developments in viral engineering techniques. To better target tumours and replicate inside cancer cells, researchers are creating modified viruses. These developments have helped oncolytic viral therapy become more successful and therapeutic. Our capacity to create targeted medicines rises in tandem with our knowledge of cancer biology. To combat cancer, oncolytic virus therapy exploits cancer cells' sensitivity to viral infection and their compromised antiviral defences. Oncolytic virus therapies have been developed to specifically target and destroy cancer cells while sparing normal healthy cells, thanks to our expanding understanding of cancer biology.
Oncolytic viral therapy has a great deal of untapped promise across a wide range of cancer subtypes and applications. There is potential to further investigate the efficacy of oncolytic viruses in treating various cancer subtypes and stages, as well as to broaden the indications for their usage. Treatment outcomes can be improved by combining oncolytic viral therapy with chemotherapy, immunotherapy, or targeted treatments. Preclinical and clinical research has demonstrated the potential of combining oncolytic viruses with other therapy. Better patient responses and therapeutic outcomes may be achieved through the investigation and optimisation of combination treatments.
Worldwide, the health care system was tested to its limits by the covid-19 epidemic. The significant global increase in covid-19 cases had a chilling effect on the development of the oncolytic viral therapy business as patients delayed treatment. It was also possible for patients with cancer to deteriorate rapidly. Furthermore, the lockdown impacted market expansion because it disrupted supply chains and prevented hospitals from installing new medical equipment.
Research and development of oncolytic virus therapies has seen a significant uptick in North America, particularly the United States. The region's established infrastructure for clinical trials, robust partnerships between academics and business, and innovation-friendly regulatory frameworks are all assets. Several oncolytic virus medicines have been approved in North America, and more clinical trials are underway. Market share estimates place this area's share at 45.2% or higher. There is significant interest in Europe in oncolytic virus therapy as well. There are now several clinical trials and research programmes in Europe that are evaluating oncolytic viruses as potential therapies for cancer. The availability of oncolytic virus medicines is made possible by the frameworks set up by European regulatory agencies for their approval and commercialization. About 30.7% of the global market is located in Europe.
Report Coverage
Global Oncolytic Virus Therapy research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Oncolytic Virus Therapy report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Oncolytic Virus Therapy competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Oncolytic Virus Therapy market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Targovax, PsiOxus Therapeutics Ltd., Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Transgene SA, VCN Biosciences, Lokon Pharma AB |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Oncolytic Virus Therapy Market from 2021 to 2030.
- Market Forecast for Oncolytic Virus Therapy Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Oncolytic Virus Therapy competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Oncolytic Virus Therapy
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Oncolytic Virus Therapy market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Oncolytic Virus Therapy market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Targovax, PsiOxus Therapeutics Ltd., Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Transgene SA, VCN Biosciences, Lokon Pharma AB
Primary Target Market
- Market Players of Oncolytic Virus Therapy
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Oncolytic Virus Therapy market based on the below-mentioned segments:
Global Oncolytic Virus Therapy Market, By Type
Adenovirus
Herpes Simplex Virus (HSV)
Measles Virus
Reovirus
Vaccinia Virus
Vesicular Stomatitis Virus (VSV)
Others
Global Oncolytic Virus Therapy market, By Application
Solid Tumors
Hematological Malignancies
Global Oncolytic Virus Therapy Market, By End User
Hospitals
Cancer Research Institutes
Biopharmaceutical Companies
Global Oncolytic Virus Therapy market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive oncolytic virus therapy market market research and competitor analysis for your business to help you develop more profound insights into the oncolytic virus therapy market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the oncolytic virus therapy market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.